Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids

In this nonsystematic review and opinion, including articles primarily selected from PubMed, we examine the pharmacological and nonpharmacological treatments of neonatal abstinence syndrome (NAS) in order to craft a reasonable opinion to help forge a paradigm shift in the treatment and prevention of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceccanti, Mauro, Blum, Kenneth, Bowirrat, Abdalla, Dennen, Catherine A., Braverman, Eric R., Baron, David, Mclaughlin, Thomas, Giordano, John, Gupta, Ashim, Downs, Bernard W., Bagchi, Debasis, Barh, Debmalya, Elman, Igor, Thanos, Panayotis K., Badgaiyan, Rajendra D., Edwards, Drew, Gold, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782293/
https://www.ncbi.nlm.nih.gov/pubmed/36556236
http://dx.doi.org/10.3390/jpm12122015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782293/
https://www.ncbi.nlm.nih.gov/pubmed/36556236
http://dx.doi.org/10.3390/jpm12122015

Ejemplares similares